This research study involves broad usage of both secondary and primary data sources. The research process involves the identification of numerous factors which affect the industry, comprising the market environment, government policy, historical data, present trends in the market, competitive landscape, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges.

Market Estimation

Top-down and bottom-up approaches are used for validating the market size for companies, regional segments along with relevant market segmentations such as product type and application.
This report includes market estimations which are based on the marketed sale price of a product. Further breakdown of product segments, particular market share are formed based on the weightage assigned to every segment, which is derived of their usage rate and average price. The entire probable factors which effect the markets and influence them in a great way are included in this research report; and have been accounted for, studied in-depth and are confirmed through primary research. These are then studies to get the final qualitative and quantitative data. Any of the factors such as the outcome of inflation, economic downfall, and any kind of policy and regulatory alterations and/or other such factors are not accounted for in the market forecast. All of this data is amalgamated and included with thorough inputs and analysis from Gravitas Market Insights is curated in this report.

Along with the previously mentioned approaches, various data triangulation methods, in order to conduct market estimations and market forecasting for the complete market segments are detailed in this report. Key Companies present in the said market are also acknowledged via in-depth secondary research and primary research.

Section 1: Executive Summary

1.1. Immunology Market Industry 360° outline, Year 2016 – 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Diseases Indication Trends
1.5. Regional Trends

Section 2: Market Dynamics - Immunology Market Industry Insights

2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter’s Analysis
2.6. Worldwide Industry Landscape, Year 2016 – 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment

Section 3: Global Immunology Market, By Drug Class

3.1. Segmentation Analysis, By Drug Class, 2016-2028
3.2. Market Share Segmentation Analysis, By Drug Class, 2016-2028
3.3. Fusion Proteins
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.4. Monoclonal antibody (mAb)
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.5. Immunosuppressant
3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.6. Polyclonal antibody (pAb)
3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.7. Other Drug Class
3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

Section 4: Global Immunology Market, By Distribution channel

4.1. Segmentation Analysis, By Distribution channel, 2016-2028
4.2. Market Share Segmentation Analysis, By Distribution channel, 2016-2028
4.3. Retail Pharmacies
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.4. Hospital Pharmacies
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.5. Online Pharmacies
4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.6. Other Distribution channels
4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

Section 5: Global Immunology Market, By Diseases Indication

5.1. Segmentation Analysis, By Diseases Indication, 2016-2028
5.2. Market Share Segmentation Analysis, By Diseases Indication, 2016-2028
5.3. Psoriatic Arthritis
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.4. Ankylosing Spondylitis
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.5. Rheumatoid Arthritis
5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.6. Prophylaxis of Organ Rejection
5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.7. Inflammatory Bowel Disease
5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.8. Plaque Psoriasis
5.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.9. Others
5.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

Section 6: Global Immunology Market, Regional Analysis

6.1. Global Immunology Market, Regional Analysis

6.2. North America, Country level Analysis
6.2.1. North America Immunology Market estimates and forecast with Growth rate analysis, By Drug Class, 2016 – 2028
6.2.2. North America Immunology Market estimates and forecast with Growth rate analysis, By Distribution channel, 2016 – 2028
6.2.3. North America Immunology Market estimates and forecast with Growth rate analysis, By Diseases Indication, 2016 – 2028
6.2.4. United States
6.2.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.2.5. Canada
6.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.2.6. Mexico
6.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

6.3. Europe Country level Analysis
6.3.1. Europe Immunology Market estimates and forecast with Growth rate analysis, By Drug Class, 2016 – 2028
6.3.2. Europe Immunology Market estimates and forecast with Growth rate analysis, By Distribution channel, 2016 – 2028
6.3.3. Europe Immunology Market estimates and forecast with Growth rate analysis, By Diseases Indication, 2016 – 2028
6.3.4. UK
6.3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.5. Germany
6.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.6. France
6.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.7. Italy
6.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.8. Spain
6.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.9. Russia
6.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.10. Rest of Europe
6.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

6.4. Asia-Pacific Country level Analysis
6.4.1. Asia-Pacific Immunology Market estimates and forecast with Growth rate analysis, By Drug Class, 2016 – 2028
6.4.2. Asia-Pacific Immunology Market estimates and forecast with Growth rate analysis, By Distribution channel, 2016 – 2028
6.4.3. Asia-Pacific Immunology Market estimates and forecast with Growth rate analysis, By Diseases Indication, 2016 – 2028
6.4.4. China
6.4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.5. India
6.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.6. Japan
6.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.7. Korea
6.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.8. Australia
6.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.9. Southeast Asia
6.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.10. Rest of Asia-Pacific
6.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

6.5. South America Country level Analysis
6.5.1. South America Immunology Market estimates and forecast with Growth rate analysis, By Drug Class, 2016 – 2028
6.5.2. South America Immunology Market estimates and forecast with Growth rate analysis, By Distribution channel, 2016 – 2028
6.5.3. South America Immunology Market estimates and forecast with Growth rate analysis, By Diseases Indication, 2016 – 2028
6.5.4. Brazil
6.5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.5. Argentina
6.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.6. Colombia
6.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.7. Rest of South America
6.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

6.6. Middle East & Africa Country level Analysis
6.6.1. MEA Immunology Market estimates and forecast with Growth rate analysis, By Drug Class, 2016 – 2028
6.6.2. MEA Immunology Market estimates and forecast with Growth rate analysis, By Distribution channel, 2016 – 2028
6.6.3. MEA Immunology Market estimates and forecast with Growth rate analysis, By Diseases Indication, 2016 – 2028
6.6.4. GCC
6.6.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.6.5. South Africa
6.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.6.6. Rest of Middle East & Africa
6.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028

Section 7: Company Profile - Immunology Market

7.1.  Janssen Global Service,LLC (Johnson & Johnson)
7.1.1. Business Overview
7.1.2. Product & Service Offering
7.1.3. Overall Revenue
7.1.4. Strategic Outlook

7.2. Abbvie Inc.
7.2.1. Business Overview
7.2.2. Product & Service Offering
7.2.3. Overall Revenue
7.2.4. Strategic Outlook

7.3. Amgen Inc.
7.3.1. Business Overview
7.3.2. Product & Service Offering
7.3.3. Overall Revenue
7.3.4. Strategic Outlook

7.4. F. Hoffmann-La Roche Ltd
7.4.1. Business Overview
7.4.2. Product & Service Offering
7.4.3. Overall Revenue
7.4.4. Strategic Outlook

7.5. Pfizer Inc.
7.5.1. Business Overview
7.5.2. Product & Service Offering
7.5.3. Overall Revenue
7.5.4. Strategic Outlook

7.6. Astellas
7.6.1. Business Overview
7.6.2. Product & Service Offering
7.6.3. Overall Revenue
7.6.4. Strategic Outlook

7.7. Novartis AG
7.7.1. Business Overview
7.7.2. Product & Service Offering
7.7.3. Overall Revenue
7.7.4. Strategic Outlook

7.8. Merck Sharp & Dohme Corp.
7.8.1. Business Overview
7.8.2. Product & Service Offering
7.8.3. Overall Revenue
7.8.4. Strategic Outlook

7.9. Bristol-Myers Squibb Company.
7.9.1. Business Overview
7.9.2. Product & Service Offering
7.9.3. Overall Revenue
7.9.4. Strategic Outlook

7.10. ALLERGAN
7.10.1. Business Overview
7.10.2. Product & Service Offering 
7.10.3. Overall Revenue
7.10.4. Strategic Outlook

7.11. UCB SA
7.11.1. Business Overview
7.11.2. Product & Service Offering
7.11.3. Overall Revenue
7.11.4. Strategic Outlook

*Market size and forecast will be provided from 2016-2028, and forecast period would be 2021-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis